Company Overview of Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. provides human prescription medicines. It offers pharmaceutical products for the treatment of lung health, cardiovascular diseases, men's prostate health, and anti-viral therapy. Its products include angiotensin II receptor blocker Micardis tablets for the reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients who are unable to take angiotensin-converting enzyme inhibitors; and COMBIVENT RESPIMAT, an inhaler for patients with chronic obstructive pulmonary disease. The company’s products also comprise Flibanserin for the treatment of hypoactive sexual desire disorder in pre-menopausal women; SPIRIVA Ha...
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877-0368
Founded in 1971
Key Executives for Boehringer Ingelheim Pharmaceuticals, Inc.
Director of Office of Diversity and Inclusion
Manager of Communications and Public Relations
Compensation as of Fiscal Year 2015.
Boehringer Ingelheim Pharmaceuticals, Inc. Key Developments
Boehringer Ingelheim Announces Enrollment of First U.S. Patients in RE-DUAL PCI and RE-CIRCUIT Trials Evaluating Pradaxa
Jul 29 15
Boehringer Ingelheim announced that the first U.S. patients have been enrolled in two of the company's international clinical trials, RE-DUAL PCI (NCT02164864) and RE-CIRCUIT (NCT02348723). RE-DUAL PCI will evaluate the efficacy and safety of Pradaxa® (dabigatran etexilate mesylate) in patients with non-valvular atrial fibrillation (NVAF) who have undergone percutaneous coronary intervention (PCI), also known as angioplasty, with stent placement. RE-CIRCUIT will evaluate the safety of PRADAXA in NVAF patients undergoing a first ablation procedure, which is conducted to help prevent heart rhythm problems. Both trials are part of Boehringer Ingelheim's extensive RE-VOLUTION® clinical trial program for PRADAXA. The program includes 14 studies and is expected to involve more than 50,000 patients in more than 44 countries globally. PRADAXA was initially approved by the FDA in 2010 to reduce the risk of stroke and systemic embolism in patients with NVAF. In 2014, the FDA approved two additional indications for PRADAXA for the treatment of DVT and PE in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. Pradaxa (dabigatran etexilate mesylate) capsules is indicated: to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation; for the treatment of deep venous thrombosis and pulmonary embolism in patients who have been treated with a parenteral anticoagulant for 5-10 days; to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in patients who have been previously treated.
Boehringer Ingelheim Enters License Agreement with Hanmi Pharmaceutical Co., Ltd
Jul 28 15
Boehringer Ingelheim and Hanmi Pharmaceutical Co., Ltd. announced an exclusive license and collaboration agreement for the development and global commercialization rights, except South Korea, China and Hong Kong, of HM61713, a novel 3rd generation EGFR targeted therapy for the treatment of a specific type of lung cancer. Under the terms of the agreement, Hanmi will receive an initial payment of USD 50 million and is entitled to potential milestone payments of USD 680 million plus tiered double-digit royalties on future net sales. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, similar requirements outside the U.S., and other customary closing conditions. HM61713 is a novel 3rd generation, orally active, irreversible EGFR mutation selective tyrosine kinase inhibitor (TKI). At this year's ASCO Annual Meeting, interim results of the Phase I/II clinical trial were presented and showed strong efficacy signals, combined with a favorable safety profile. The compound is currently in Phase II clinical development for patients with non-small cell lung cancer (NSCLC) with T790M mutations who have developed resistance to previous EGFR targeting agents. Preparations have begun for a broader Phase III trial program to be initiated in 2016. HM61713 is another important pillar in Boehringer Ingelheim's global lung cancer franchise, which builds on two products, GIOTRIF®/GILOTRIF® (afatinib) and VARGATEF® (nintedanib), approved in various countries.
Boehringer Ingelheim Pharmaceuticals, Inc. Announces Stiolto Respimat Now Available in the United States for the Treatment of COPD
Jun 30 15
Boehringer Ingelheim Pharmaceuticals, Inc. announced that STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States. In May 2015, the U.S. Food and Drug Administration (FDA) approved STIOLTO RESPIMAT for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). STIOLTO RESPIMAT is not indicated to treat asthma or acute deterioration of COPD. The company will offer a savings card that will allow most eligible patients to get STIOLTO RESPIMAT at no cost for 12 consecutive months, depending on their insurance provider.
Similar Private Companies By Industry
Recent Private Companies Transactions